BruceantarinCAS# 41451-76-7 |
2D Structure
Quality Control & MSDS
Package In Stock
Number of papers citing our products
Cas No. | 41451-76-7 | SDF | Download SDF |
PubChem ID | N/A | Appearance | Powder |
Formula | C28H30O11 | M.Wt | 542.53 |
Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Bruceantarin Dilution Calculator
Bruceantarin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.8432 mL | 9.2161 mL | 18.4322 mL | 36.8643 mL | 46.0804 mL |
5 mM | 0.3686 mL | 1.8432 mL | 3.6864 mL | 7.3729 mL | 9.2161 mL |
10 mM | 0.1843 mL | 0.9216 mL | 1.8432 mL | 3.6864 mL | 4.608 mL |
50 mM | 0.0369 mL | 0.1843 mL | 0.3686 mL | 0.7373 mL | 0.9216 mL |
100 mM | 0.0184 mL | 0.0922 mL | 0.1843 mL | 0.3686 mL | 0.4608 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2-Mialine
Catalog No.:BCX1690
CAS No.:634-97-9
- Glycoside St-J
Catalog No.:BCX1689
CAS No.:203513-88-6
- Protoapigenone
Catalog No.:BCX1688
CAS No.:862884-32-0
- Flaccidoside III
Catalog No.:BCX1687
CAS No.:140400-67-5
- Paclobutrazol
Catalog No.:BCX1686
CAS No.:76738-62-0
- 2'- O -Acetylthevetin B
Catalog No.:BCX1685
CAS No.:82145-55-9
- (1β,2β,3β,4β,5β,7α,22α)-27-(β-D-Glucopyranosyloxy)-1,2,3,4,5,7,22-heptahydroxyfurost-25-en-6-one
Catalog No.:BCX1684
CAS No.:1013405-26-9
- Rubrofusarin
Catalog No.:BCX1683
CAS No.:3567-00-8
- (7’S)-N-trans-Feruloylnormetanephrine
Catalog No.:BCX1682
CAS No.:2705170-78-9
- 2'- O -Acetylthevetin A
Catalog No.:BCX1681
CAS No.:1356494-03-5
- Cannogenol 3-O-β-gentiobiosyl-(1→4)-α-L-thevetoside
Catalog No.:BCX1680
CAS No.:1841524-78-4
- α-Thevetin B
Catalog No.:BCX1679
CAS No.:144300-21-0
- (+)-(3’S,4’R)-3’-acetyl-4’-isobutyrylkhellactone
Catalog No.:BCX1692
CAS No.:1562996-11-5
- Arborescosidic acid
Catalog No.:BCX1693
CAS No.:325798-51-4
- Apigenin-7-O-diglucuronoside
Catalog No.:BCX1694
CAS No.:119738-57-7
- Complanatin II
Catalog No.:BCX1695
CAS No.:142449-94-3
- Ladanetin-6-O-β-(6''-O- acetyl)glucoside
Catalog No.:BCX1696
CAS No.:1256959-27-9
- Cirsiliol 4'-glucoside
Catalog No.:BCX1697
CAS No.:41087-98-3
- Pedaliin 6''-acetate
Catalog No.:BCX1698
CAS No.:160789-41-3
- Ladanetin-6-O-β-D-glucopyranoside
Catalog No.:BCX1699
CAS No.:89647-63-2
- Homoveratric acid
Catalog No.:BCX1700
CAS No.:93-40-3
- Scutellarein-7-O-diglucuronide
Catalog No.:BCX1701
CAS No.:150641-65-9
- Alismanol M
Catalog No.:BCX1702
CAS No.:2408810-59-1
- Celangulin V
Catalog No.:BCX1703
CAS No.:139979-81-0
Combining empirical knowledge, in silico molecular docking and ADMET profiling to identify therapeutic phytochemicals from Brucea antidysentrica for acute myeloid leukemia.[Pubmed:35895695]
PLoS One. 2022 Jul 27;17(7):e0270050.
Acute myeloid leukemia (AML) is one of the deadly cancers. Chemotherapy is the first-line treatment and the only curative intervention is stem cell transplantation which are intolerable for aged and comorbid patients. Therefore, finding complementary treatment is still an active research area. For this, empirical knowledge driven search for therapeutic agents have been carried out by long and arduous wet lab processes. Nonetheless, currently there is an accumulated bioinformatics data about natural products that enabled the use of efficient and cost effective in silico methods to find drug candidates. In this work, therefore, we set out to computationally investigate the phytochemicals from Brucea antidysentrica to identify therapeutic phytochemicals for AML. We performed in silico molecular docking of compounds against AML receptors IDH2, MCL1, FLT3 and BCL2. Phytochemicals were docked to AML receptors at the same site where small molecule drugs were bound and their binding affinities were examined. In addition, random compounds from PubChem were docked with AML targets and their docking score was compared with that of phytochemicals using statistical analysis. Then, non-covalent interactions between phytochemicals and receptors were identified and visualized using discovery studio and Protein-Ligand Interaction Profiler web tool (PLIP). From the statistical analysis, most of the phytochemicals exhibited significantly lower (p-value = 0.05) binding energies compared with random compounds. Using cutoff binding energy of less than or equal to one standard deviation from the mean of the phytochemicals' binding energies for each receptor, 12 phytochemicals showed considerable binding affinity. Especially, hydnocarpin (-8.9 kcal/mol) and yadanzioside P (-9.4 kcal/mol) exhibited lower binding energy than approved drugs AMG176 (-8.6 kcal/mol) and gilteritinib (-9.1 kcal/mol) to receptors MCL1 and FLT3 respectively, indicating their potential to be lead molecules. In addition, most of the phytochemicals possessed acceptable drug-likeness and absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties. Based on the binding affinities as exhibited by the molecular docking studies supported by the statistical analysis, 12 phytochemicals from Brucea antidysentrica (1,11-dimethoxycanthin-6-one, 1-methoxycanthin-6-one, 2-methoxycanthin-6-one, beta-carboline-1-propionic acid, bruceanol A, bruceanol D, bruceanol F, Bruceantarin, bruceantin, canthin-6-one, hydnocarpin, and yadanzioside P) can be considered as candidate compounds to prevent and manage AML. However, the phytochemicals should be further studied using in vivo & in vitro experiments on AML models. Therefore, this study concludes that combination of empirical knowledge, in silico molecular docking and ADMET profiling is useful to find natural product-based drug candidates. This technique can be applied to other natural products with known empirical efficacy.